Sanofi has faced periodic corporate and market headwinds stemming from intense generic competition for legacy blockbuster drugs, shifting research and development pipelines in immunology and oncology, and heavy capital investments required to pivot toward advanced biological medicines and mRNA technologies. Additionally, broader pricing pressures in key international pharmaceutical markets and strategic corporate restructuring have impacted its short-term operational margins.